Federated Hermes’s Eledon Pharmaceuticals ELDN Stock Holding History

Federated Hermes’s Portfolio ELDN Stock Details ELDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-339	Closed	-$1K	–	2192
2022 Q3	$1K	Sell	339 -67	-17%	-$213	﹤0.01%	2034
2022 Q2	$1K	Sell	406 -197	-33%	-$601	﹤0.01%	2037
2022 Q1	$2K	Buy	603 +392	+186%	+$1.52K	﹤0.01%	2021
2021 Q4	$1K	Buy	+211	New	+$1.07K	﹤0.01%	2110

Other funds holding ELDN

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return

CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

JMAC Enterprises Newtown, Pennsylvania $593M AUM 22.22% 1-Year Est. Return

Federated Hermes's ELDN Position: Q4 2022 in Review

Federated Hermes sold out of Eledon Pharmaceuticals (ELDN) in Q4 2022, closing a stake of 339 shares — an estimated $1K sold.

Federated Hermes first reported a position in ELDN in Q4 2021 and held it in 4 quarters. The position peaked at $2K in Q1 2022. 28 funds tracked by Wall St. Rank hold ELDN as of Q4 2022.

Federated Hermes reported no remaining Eledon Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
Federated Hermes sold 339 Eledon Pharmaceuticals shares in Q4 2022, an estimated $1K.
Federated Hermes first reported a position in Eledon Pharmaceuticals in Q4 2021 and held it in 4 quarters.
Federated Hermes's Eledon Pharmaceuticals position peaked at $2K in Q1 2022.
28 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q4 2022.

Based on Federated Hermes's 13F filing for Q4 2022, filed 13 Feb 2023.